Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

NCT02339064 is registered in ClinicalTrials.gov with MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals as lead sponsor.

NCT NCT02339064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02339064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 28, 2015
Completion date
December 31, 2025
Enrollment
99 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease